Researchers are looking into stem cell therapies as potential treatments for a variety of multiple sclerosis conditions. The findings are promising, but experts say there still is a lot of work to be done.
The Food and Drug Administration has recently announced the approval of the first biosimilar treatment for multiple sclerosis, called Tyruko, which provides a potentially more cost-effective alternative to Tysabri.